ClinicalTrials.gg
RecruitingNCT07684131Ewall Obs 2022Updated Jul 6, 2026

EWALL-PH OBSERVARTORY 2022

An observational study in Acute Lymphoblastic Leukemia, sponsored by Versailles Hospital. Recruiting at 23 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Versailles Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France — 29 open to participants now, 40 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · France.

Planned enrollment
17th of 35
100 · median 100
Started
2024
with 2 others
Observational
35 of 152
7 open now
Primary completion
2027-06
later than 15 of 39 live
Registered
151st of 152
by date
Lead sponsor
5 of 152
Versailles Hospital

Among the 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France, this one is the 17th largest by planned enrollment of the 35 observational ones that give a count, is one of 3 that started in 2024, is one of 35 observational ones, reaches primary completion later than 15 of the 39 other live ones, and was the 151st registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

29 of the 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France, or all of them as a file.
02

Study summary

An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Acute Lmphoblastic Leukaemia with Philadelphia chromosome or BCR::ABL1 positive

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years
  2. Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia
  3. Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody

Exclusion criteria

Exclusion Criteria:

  1. Patients deceded and having previously refused data collection
  2. Not included in a prospective clinical trial
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Overall survival by 12 months

    Time frame: 12 months

Secondary outcomes

  1. overal survival by 36 months

    Time frame: 36 months

  2. proportion of complete remission

    Time frame: 36 months

  3. the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood

    Time frame: 36 months

  4. the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood

    Time frame: 36 months

  5. Event free survival

    Time frame: 36 months

  6. Relapse free survival

    Time frame: 36 months

  7. the incidence ofBCR..ABL1 TK mutations

    Time frame: 36 months

  8. treatment tolerance

    Time frame: 36 months

  9. Death during induction

    Time frame: 2 months

  10. Death in complete remission

    Time frame: 36 months

07

Study locations

7 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 41 months is below that.

Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2026
First posted
Jul 6, 2026
StartActual
Jan 15, 2024
Primary completionEst.
Jun 15, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07684131
Lead sponsor
Versailles Hospital
Responsible party
Philippe ROUSSELOT (Professor, Versailles Hospital) — Principal investigator
First posted
Jul 6, 2026
Start date
Jan 15, 2024
Primary completion
Jun 15, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Sandrine Roux
Contact
sroux@ght78sud.fr
+33139239777

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion